LONGBOARD PHARMACEUTICALS IN (LBPH)
US54300N1037 - Common Stock
Investors Snag LBPH 14.1% Cheaper Than Its Secondary Stock Offering
Commit To Purchase Longboard Pharmaceuticals At $12.50, Earn 18.6% Annualized Using Options
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard stock up 8% as Citi initiates at buy, citing takeover potential (NASDAQ:LBPH)
Longboard Pharmaceuticals (LBPH) shares were up 8% Friday after Citigroup initiated coverage of the stock with a buy rating, citing its potential as a takeover
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
Commit To Buy Longboard Pharmaceuticals At $22.50, Earn 43.4% Annualized Using Options
Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher
You might say that this biotech stock is magnificent.
Investors Pick Up LBPH Even Cheaper Than Its Secondary Stock Offering
Longboard Pharmaceuticals raises ~$241.5M through public offering of shares (NASDAQ:LBPH)
Longboard Pharmaceuticals (LBPH) said on Monday that it has closed an underwritten public offering of 11.5M shares, having raised ~$241.5M.
Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Longboard Pharmaceuticals prices upsized stock offering to raise $210 million
Longboard Pharmaceuticals (LBPH) on Wednesday priced an upsized underwritten public offering of 10 million shares of its voting common stock at $21.00 per share, for an expected gross procee
Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Longboard stock rockets 316% on positive data (NASDAQ:LBPH)
Longboard Pharmaceuticals (LBPH) stock rocketed 316% Tuesday following positive data from a Phase 1b/2a study for its drug bexicaserin. Read more here.
Why Longboard Pharma Catapulted 316%, Leading A Biotech Stock Rally
Longboard Pharmaceuticals is working on treatments for seizure disorders.
Longboard Pharmaceuticals commences $150M public offering (NASDAQ:LBPH)
Longboard Pharmaceuticals (LBPH) said Tuesday evening that it has commenced a $150M underwritten public offering of its voting common stock. The biotech company
Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc.
Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today?
With Longboard Pharmaceuticals delivering positive clinical trial data, LBPH stock soared on the positive therapeutic implications.
Tuesday Sector Leaders: Drugs, Biotechnology Stocks
Neurology-Focused Longboard Pharmaceuticals' Stock Soars Over 200% Today - Here's Why
Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental
Longboard stock soars 132% in premarket trading on positive data (NASDAQ:LBPH)
Longboard Pharmaceuticals (LBPH) stock soared 132% in pre-market trading following positive data from a Phase 1b/2a study for its drug bexicaserin. Read more here.